OrphoMed is a San Francisco-based clinical-stage biopharmaceutical company developing dimer therapies. Its lead candidate, ORP-101, is a metabolically stable partial agonist of the μ opioid receptor and antagonist of the κ opioid receptor designed to mitigate abdominal pain and gastric hypermotility in irritable bowel syndrome with diarrhea (IBS-D) without CNS penetration. In multiple clinically relevant animal models ORP-101 suppressed general and colon-specific hyperalgesic signals and has been shown not to cause constriction of the sphincter of Oddi, which can lead to acute pancreatitis with some μ agonists. ORP-101 is a proprietary molecule fully owned by OrphoMed with no downstream royalties or milestone payments. The company closed a $39M Series A financing led by New Enterprise Associates with co-lead Takeda Ventures and participation from Pappas Capital (Pappas Ventures V), Relativity Healthcare Partners and the Mario Family Fund. Proceeds will be used to advance clinical development of ORP-101 for IBS-D.

Total raised

$39M

Funding rounds

1

Latest round

Series A

Latest activity

May 2017